BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38481255)

  • 21. Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis.
    Rusthoven CG; Koshy M; Sher DJ; Ney DE; Gaspar LE; Jones BL; Karam SD; Amini A; Ormond DR; Youssef AS; Kavanagh BD
    JAMA Neurol; 2016 Jul; 73(7):821-8. PubMed ID: 27214765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review and meta-analysis of the impact of radiation-related lymphopenia on outcomes in pancreatic cancer.
    Venkatesulu BP; Chan DP; Giridhar P; Upadhyay R; Sharma A; Elghazawy H; Elumalai T; V P; Mallick S; Hsieh CE
    Future Oncol; 2022 May; 18(15):1885-1895. PubMed ID: 35132868
    [No Abstract]   [Full Text] [Related]  

  • 23. The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
    Brenner A; Friger M; Geffen DB; Kaisman-Elbaz T; Lavrenkov K
    Oncology; 2019; 97(5):255-263. PubMed ID: 31288238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temozolomide for high grade glioma.
    Hart MG; Garside R; Rogers G; Stein K; Grant R
    Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD007415. PubMed ID: 23633341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
    McBain C; Lawrie TA; Rogozińska E; Kernohan A; Robinson T; Jefferies S
    Cochrane Database Syst Rev; 2021 May; 5(1):CD013579. PubMed ID: 34559423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
    Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
    J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons.
    Mohan R; Liu AY; Brown PD; Mahajan A; Dinh J; Chung C; McAvoy S; McAleer MF; Lin SH; Li J; Ghia AJ; Zhu C; Sulman EP; de Groot JF; Heimberger AB; McGovern SL; Grassberger C; Shih H; Ellsworth S; Grosshans DR
    Neuro Oncol; 2021 Feb; 23(2):284-294. PubMed ID: 32750703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Steroids use and survival in patients with glioblastoma multiforme: a pooled analysis.
    Petrelli F; De Stefani A; Ghidini A; Bruschieri L; Riboldi V; Dottorini L; Iaculli A; Zaniboni A; Trevisan F
    J Neurol; 2021 Feb; 268(2):440-447. PubMed ID: 32002651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
    Gilbert MR; Wang M; Aldape KD; Stupp R; Hegi ME; Jaeckle KA; Armstrong TS; Wefel JS; Won M; Blumenthal DT; Mahajan A; Schultz CJ; Erridge S; Baumert B; Hopkins KI; Tzuk-Shina T; Brown PD; Chakravarti A; Curran WJ; Mehta MP
    J Clin Oncol; 2013 Nov; 31(32):4085-91. PubMed ID: 24101040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Influence of Severe Radiation-Induced Lymphopenia on Overall Survival in Solid Tumors: A Systematic Review and Meta-Analysis.
    Damen PJJ; Kroese TE; van Hillegersberg R; Schuit E; Peters M; Verhoeff JJC; Lin SH; van Rossum PSN
    Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):936-948. PubMed ID: 34329738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma.
    Wakabayashi T; Natsume A; Mizusawa J; Katayama H; Fukuda H; Sumi M; Nishikawa R; Narita Y; Muragaki Y; Maruyama T; Ito T; Beppu T; Nakamura H; Kayama T; Sato S; Nagane M; Mishima K; Nakasu Y; Kurisu K; Yamasaki F; Sugiyama K; Onishi T; Iwadate Y; Terasaki M; Kobayashi H; Matsumura A; Ishikawa E; Sasaki H; Mukasa A; Matsuo T; Hirano H; Kumabe T; Shinoura N; Hashimoto N; Aoki T; Asai A; Abe T; Yoshino A; Arakawa Y; Asano K; Yoshimoto K; Shibui S;
    J Neurooncol; 2018 Jul; 138(3):627-636. PubMed ID: 29557060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma-Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation.
    Krauze AV; Zhao Y; Li MC; Shih J; Jiang W; Tasci E; Cooley Zgela T; Sproull M; Mackey M; Shankavaram U; Tofilon P; Camphausen K
    Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis.
    Kaka N; Hafazalla K; Samawi H; Simpkin A; Perry J; Sahgal A; Das S
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31689995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
    Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR
    J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value and Risk Factors of Treatment-Related Lymphopenia in Malignant Glioma Patients Treated With Chemoradiotherapy: A Systematic Review and Meta-Analysis.
    Zhang Y; Chen S; Chen H; Chen S; Li Z; Feng E; Li W
    Front Neurol; 2021; 12():726561. PubMed ID: 35058869
    [No Abstract]   [Full Text] [Related]  

  • 37. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
    Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis.
    Sareen H; Ma Y; Becker TM; Roberts TL; de Souza P; Powter B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis.
    Seliger C; Genbrugge E; Gorlia T; Chinot O; Stupp R; Nabors B; Weller M; Hau P;
    Int J Cancer; 2020 Feb; 146(3):803-809. PubMed ID: 30980539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide.
    Faustino AC; Viani GA; Hamamura AC
    Clinics (Sao Paulo); 2020; 75():e1553. PubMed ID: 32935821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.